http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109468381-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate | 2018-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109468381-B |
| titleOfInvention | Methylation sites and detection primers for cervical cancer screening |
| abstract | The invention discloses a methylation site for cervical cancer screening, the methylation site is cg24575234 site of CHRM2 gene, cg06818777 site of CHAD gene, cg08361126 site of FGF10 gene and ITGA8 gene cg08976810 site, and also disclosed the primer pair included in the kit for detecting gene methylation level of cervical cancer samples. The present invention can be fully automated, the results are objective, easy to interpret, and avoid the influence of subjective factors; the specificity of the present invention for detecting and screening cervical cancer is 100%, greater than the specificity (80%) of the HPV gene detection method, and positive prediction The value increased from 0.0474% to 100%, and the screening results were objective and easy to interpret. The present invention can also be used in parallel with the current cervical cancer screening test, which greatly saves the cost of examination and avoids economic loss and psychological burden caused by too many false positive patients due to positive results. |
| priorityDate | 2018-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.